Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWE7B9)

Drug Name

CX-4945 Drug Info

Synonyms

1009820-21-6; Silmitasertib; CX-4945; 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid; 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid; C6RWP0N0L2; CHEMBL1230165; AK-82006; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-Carboxylic Acid; 5-((3-Chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic acid; C19H12ClN3O2; W-204393

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus infection	1D92	Phase 2	[1]
Cholangiocarcinoma	2C12.10	Phase 1/2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

PubChem CID: 24748573
CAS Number: CAS 1009820-21-6
TTD Drug ID: DMWE7B9
VARIDT Drug ID: DR00803

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase II (CSNK2)	TTZ5NI7	NOUNIPROTAC	Modulator	[4]
Casein kinase II alpha (CSNK2A1)	TTER6YH	CSK21_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Casein kinase II alpha (CSNK2A1)	DTT	CSNK2A1	5.162	6.628	6.981	6.144

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Coronavirus infection

ICD Disease Classification

1D92

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Casein kinase II alpha (CSNK2A1)	DTT	CSNK2A1	6.82E-04	0.29	2.43

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04668209) Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) (CX4945). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8126).
4	CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.